Post-radiotherapy prostate biopsies reveal heightened apex positivity relative to other prostate regions sampled

Kris T. Huang, Radka Stoyanova, Gail Walker, Kiri Sandler, Matthew Thomas Studenski, Nesrin Dogan, Tahseen Al-Saleem, Mark K. Buyyounouski, Eric M. Horwitz, Alan Pollack

Research output: Contribution to journalArticle

7 Citations (Scopus)

Abstract

Background and purpose Prostate biopsy positivity after radiotherapy (RT) is a significant determinant of eventual biochemical failure. We mapped pre- and post-treatment tumor locations to determine if residual disease is location-dependent. Materials and methods There were 303 patients treated on a randomized hypofractionation trial. Of these, 125 underwent prostate biopsy 2-years post-RT. Biopsy cores were mapped to a sextant template, and 86 patients with both pre-/post-treatment systematic sextant biopsies were analyzed. Results The pretreatment distribution of positive biopsy cores was not significantly related to prostate region (base, mid, apex; p = 0.723). Whereas all regions post-RT had reduced positive biopsies, the base was reduced to the greatest degree and the apex the least (p = 0.045). In 38 patients who had a positive post-treatment biopsy, there was change in the rate of apical positivity before and after treatment (76 vs. 71%; p = 0.774), while significant reductions were seen in the mid and base. Conclusion In our experience, persistence of prostate tumor cells after RT increases going from the base to apex. MRI was used in planning and image guidance was performed daily during treatment, so geographic miss of the apex is unlikely. Nonetheless, the pattern observed suggests that attention to apex dosimetry is a priority.

Original languageEnglish (US)
Pages (from-to)101-106
Number of pages6
JournalRadiotherapy and Oncology
Volume115
Issue number1
DOIs
StatePublished - Apr 1 2015

Fingerprint

Prostate
Radiotherapy
Biopsy
Therapeutics
Neoplasms

Keywords

  • Biopsy
  • Failure patterns
  • Post-treatment
  • Prostate

ASJC Scopus subject areas

  • Oncology
  • Radiology Nuclear Medicine and imaging
  • Hematology

Cite this

Post-radiotherapy prostate biopsies reveal heightened apex positivity relative to other prostate regions sampled. / Huang, Kris T.; Stoyanova, Radka; Walker, Gail; Sandler, Kiri; Studenski, Matthew Thomas; Dogan, Nesrin; Al-Saleem, Tahseen; Buyyounouski, Mark K.; Horwitz, Eric M.; Pollack, Alan.

In: Radiotherapy and Oncology, Vol. 115, No. 1, 01.04.2015, p. 101-106.

Research output: Contribution to journalArticle

Huang, Kris T. ; Stoyanova, Radka ; Walker, Gail ; Sandler, Kiri ; Studenski, Matthew Thomas ; Dogan, Nesrin ; Al-Saleem, Tahseen ; Buyyounouski, Mark K. ; Horwitz, Eric M. ; Pollack, Alan. / Post-radiotherapy prostate biopsies reveal heightened apex positivity relative to other prostate regions sampled. In: Radiotherapy and Oncology. 2015 ; Vol. 115, No. 1. pp. 101-106.
@article{eba1b312771543798468dc1d5740a63e,
title = "Post-radiotherapy prostate biopsies reveal heightened apex positivity relative to other prostate regions sampled",
abstract = "Background and purpose Prostate biopsy positivity after radiotherapy (RT) is a significant determinant of eventual biochemical failure. We mapped pre- and post-treatment tumor locations to determine if residual disease is location-dependent. Materials and methods There were 303 patients treated on a randomized hypofractionation trial. Of these, 125 underwent prostate biopsy 2-years post-RT. Biopsy cores were mapped to a sextant template, and 86 patients with both pre-/post-treatment systematic sextant biopsies were analyzed. Results The pretreatment distribution of positive biopsy cores was not significantly related to prostate region (base, mid, apex; p = 0.723). Whereas all regions post-RT had reduced positive biopsies, the base was reduced to the greatest degree and the apex the least (p = 0.045). In 38 patients who had a positive post-treatment biopsy, there was change in the rate of apical positivity before and after treatment (76 vs. 71{\%}; p = 0.774), while significant reductions were seen in the mid and base. Conclusion In our experience, persistence of prostate tumor cells after RT increases going from the base to apex. MRI was used in planning and image guidance was performed daily during treatment, so geographic miss of the apex is unlikely. Nonetheless, the pattern observed suggests that attention to apex dosimetry is a priority.",
keywords = "Biopsy, Failure patterns, Post-treatment, Prostate",
author = "Huang, {Kris T.} and Radka Stoyanova and Gail Walker and Kiri Sandler and Studenski, {Matthew Thomas} and Nesrin Dogan and Tahseen Al-Saleem and Buyyounouski, {Mark K.} and Horwitz, {Eric M.} and Alan Pollack",
year = "2015",
month = "4",
day = "1",
doi = "10.1016/j.radonc.2015.03.006",
language = "English (US)",
volume = "115",
pages = "101--106",
journal = "Radiotherapy and Oncology",
issn = "0167-8140",
publisher = "Elsevier Ireland Ltd",
number = "1",

}

TY - JOUR

T1 - Post-radiotherapy prostate biopsies reveal heightened apex positivity relative to other prostate regions sampled

AU - Huang, Kris T.

AU - Stoyanova, Radka

AU - Walker, Gail

AU - Sandler, Kiri

AU - Studenski, Matthew Thomas

AU - Dogan, Nesrin

AU - Al-Saleem, Tahseen

AU - Buyyounouski, Mark K.

AU - Horwitz, Eric M.

AU - Pollack, Alan

PY - 2015/4/1

Y1 - 2015/4/1

N2 - Background and purpose Prostate biopsy positivity after radiotherapy (RT) is a significant determinant of eventual biochemical failure. We mapped pre- and post-treatment tumor locations to determine if residual disease is location-dependent. Materials and methods There were 303 patients treated on a randomized hypofractionation trial. Of these, 125 underwent prostate biopsy 2-years post-RT. Biopsy cores were mapped to a sextant template, and 86 patients with both pre-/post-treatment systematic sextant biopsies were analyzed. Results The pretreatment distribution of positive biopsy cores was not significantly related to prostate region (base, mid, apex; p = 0.723). Whereas all regions post-RT had reduced positive biopsies, the base was reduced to the greatest degree and the apex the least (p = 0.045). In 38 patients who had a positive post-treatment biopsy, there was change in the rate of apical positivity before and after treatment (76 vs. 71%; p = 0.774), while significant reductions were seen in the mid and base. Conclusion In our experience, persistence of prostate tumor cells after RT increases going from the base to apex. MRI was used in planning and image guidance was performed daily during treatment, so geographic miss of the apex is unlikely. Nonetheless, the pattern observed suggests that attention to apex dosimetry is a priority.

AB - Background and purpose Prostate biopsy positivity after radiotherapy (RT) is a significant determinant of eventual biochemical failure. We mapped pre- and post-treatment tumor locations to determine if residual disease is location-dependent. Materials and methods There were 303 patients treated on a randomized hypofractionation trial. Of these, 125 underwent prostate biopsy 2-years post-RT. Biopsy cores were mapped to a sextant template, and 86 patients with both pre-/post-treatment systematic sextant biopsies were analyzed. Results The pretreatment distribution of positive biopsy cores was not significantly related to prostate region (base, mid, apex; p = 0.723). Whereas all regions post-RT had reduced positive biopsies, the base was reduced to the greatest degree and the apex the least (p = 0.045). In 38 patients who had a positive post-treatment biopsy, there was change in the rate of apical positivity before and after treatment (76 vs. 71%; p = 0.774), while significant reductions were seen in the mid and base. Conclusion In our experience, persistence of prostate tumor cells after RT increases going from the base to apex. MRI was used in planning and image guidance was performed daily during treatment, so geographic miss of the apex is unlikely. Nonetheless, the pattern observed suggests that attention to apex dosimetry is a priority.

KW - Biopsy

KW - Failure patterns

KW - Post-treatment

KW - Prostate

UR - http://www.scopus.com/inward/record.url?scp=84930756830&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84930756830&partnerID=8YFLogxK

U2 - 10.1016/j.radonc.2015.03.006

DO - 10.1016/j.radonc.2015.03.006

M3 - Article

VL - 115

SP - 101

EP - 106

JO - Radiotherapy and Oncology

JF - Radiotherapy and Oncology

SN - 0167-8140

IS - 1

ER -